Free Trial

Arbutus Biopharma (ABUS) Competitors

Arbutus Biopharma logo
$3.14 -0.11 (-3.24%)
As of 12:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ABUS vs. GMTX, IBRX, TWST, ARWR, APLS, VCEL, RXRX, NAMS, DNLI, and KNSA

Should you be buying Arbutus Biopharma stock or one of its competitors? The main competitors of Arbutus Biopharma include Gemini Therapeutics (GMTX), ImmunityBio (IBRX), Twist Bioscience (TWST), Arrowhead Pharmaceuticals (ARWR), Apellis Pharmaceuticals (APLS), Vericel (VCEL), Recursion Pharmaceuticals (RXRX), NewAmsterdam Pharma (NAMS), Denali Therapeutics (DNLI), and Kiniksa Pharmaceuticals International (KNSA). These companies are all part of the "pharmaceutical products" industry.

Arbutus Biopharma vs. Its Competitors

Arbutus Biopharma (NASDAQ:ABUS) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Arbutus Biopharma presently has a consensus target price of $5.50, indicating a potential upside of 74.88%. Given Arbutus Biopharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Arbutus Biopharma is more favorable than Gemini Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arbutus Biopharma
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Gemini Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Arbutus Biopharma has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arbutus Biopharma$6.17M97.63-$69.92M-$0.41-7.67
Gemini TherapeuticsN/AN/A-$71.87M-$1.00-54.75

43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are held by institutional investors. 20.3% of Arbutus Biopharma shares are held by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Gemini Therapeutics has a net margin of 0.00% compared to Arbutus Biopharma's net margin of -1,196.64%. Gemini Therapeutics' return on equity of -38.78% beat Arbutus Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Arbutus Biopharma-1,196.64% -75.51% -55.81%
Gemini Therapeutics N/A -38.78%-35.88%

In the previous week, Arbutus Biopharma had 1 more articles in the media than Gemini Therapeutics. MarketBeat recorded 1 mentions for Arbutus Biopharma and 0 mentions for Gemini Therapeutics. Arbutus Biopharma's average media sentiment score of 0.00 equaled Gemini Therapeutics'average media sentiment score.

Company Overall Sentiment
Arbutus Biopharma Neutral
Gemini Therapeutics Neutral

Arbutus Biopharma has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the S&P 500.

Summary

Arbutus Biopharma beats Gemini Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Arbutus Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ABUS vs. The Competition

MetricArbutus BiopharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$602.36M$2.88B$5.49B$8.96B
Dividend YieldN/A2.44%5.22%3.99%
P/E Ratio-7.6721.1627.5220.15
Price / Sales97.63285.45427.69116.17
Price / CashN/A41.7026.2128.59
Price / Book6.177.407.935.60
Net Income-$69.92M-$55.14M$3.17B$248.65M
7 Day Performance1.78%4.16%4.76%7.73%
1 Month Performance-9.63%0.80%2.87%8.63%
1 Year Performance0.80%4.44%35.20%21.67%

Arbutus Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ABUS
Arbutus Biopharma
1.4591 of 5 stars
$3.14
-3.2%
$5.50
+75.4%
+3.7%$600.45M$6.17M-7.6590
GMTX
Gemini Therapeutics
N/A$54.50
+0.7%
N/A+17.4%$2.36BN/A-54.5030High Trading Volume
IBRX
ImmunityBio
1.8477 of 5 stars
$2.64
-2.2%
$12.25
+364.0%
-57.5%$2.33B$14.74M-4.55590Negative News
Gap Up
TWST
Twist Bioscience
4.4624 of 5 stars
$36.79
+2.4%
$50.40
+37.0%
-21.4%$2.20B$312.97M-11.32990Positive News
ARWR
Arrowhead Pharmaceuticals
3.7854 of 5 stars
$15.80
-1.7%
$43.71
+176.7%
-34.4%$2.18B$3.55M-11.29400
APLS
Apellis Pharmaceuticals
4.4261 of 5 stars
$17.31
-0.7%
$40.05
+131.4%
-50.4%$2.18B$781.37M-9.67770Analyst Revision
VCEL
Vericel
2.8363 of 5 stars
$42.55
+2.0%
$61.14
+43.7%
-10.5%$2.14B$237.22M1,418.81300Positive News
RXRX
Recursion Pharmaceuticals
1.7588 of 5 stars
$5.06
+0.6%
$7.00
+38.3%
-28.1%$2.06B$58.84M-2.86400
NAMS
NewAmsterdam Pharma
2.2701 of 5 stars
$18.11
-2.5%
$42.89
+136.8%
-0.8%$2.03B$45.56M-9.634Positive News
Analyst Upgrade
DNLI
Denali Therapeutics
4.6337 of 5 stars
$13.99
-0.8%
$33.71
+141.0%
-30.5%$2.03BN/A-5.24430News Coverage
Positive News
KNSA
Kiniksa Pharmaceuticals International
3.4242 of 5 stars
$27.67
-1.3%
$38.80
+40.2%
+43.9%$2.02B$423.24M-110.68220Analyst Upgrade

Related Companies and Tools


This page (NASDAQ:ABUS) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners